Stratos Investment Management LLC Purchases 4,252 Shares of Amgen Inc. (NASDAQ:AMGN)

Stratos Investment Management LLC raised its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 24.8% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 21,382 shares of the medical research company's stock after acquiring an additional 4,252 shares during the period. Stratos Investment Management LLC's holdings in Amgen were worth $6,662,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. May Hill Capital LLC lifted its stake in shares of Amgen by 4.9% in the 1st quarter. May Hill Capital LLC now owns 1,317 shares of the medical research company's stock worth $410,000 after purchasing an additional 62 shares during the period. Horst & Graben Wealth Management LLC bought a new position in shares of Amgen in the 1st quarter worth approximately $219,000. Beverly Hills Private Wealth LLC lifted its stake in shares of Amgen by 2.3% in the 1st quarter. Beverly Hills Private Wealth LLC now owns 1,932 shares of the medical research company's stock worth $602,000 after purchasing an additional 44 shares during the period. Crossmark Global Holdings Inc. lifted its stake in shares of Amgen by 5.6% in the 1st quarter. Crossmark Global Holdings Inc. now owns 80,889 shares of the medical research company's stock worth $25,201,000 after purchasing an additional 4,282 shares during the period. Finally, U.S. Capital Wealth Advisors LLC lifted its stake in shares of Amgen by 7.8% in the 1st quarter. U.S. Capital Wealth Advisors LLC now owns 17,771 shares of the medical research company's stock worth $5,537,000 after purchasing an additional 1,291 shares during the period. Institutional investors own 76.50% of the company's stock.

Insiders Place Their Bets

In related news, SVP Rachna Khosla sold 1,500 shares of Amgen stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the sale, the senior vice president owned 8,162 shares in the company, valued at $2,364,368.16. This trade represents a 15.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.69% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

AMGN has been the topic of several recent research reports. Erste Group Bank cut shares of Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Mizuho raised their target price on shares of Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a research note on Wednesday, May 7th. Royal Bank Of Canada decreased their target price on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Morgan Stanley restated an "equal weight" rating on shares of Amgen in a research note on Friday, May 2nd. Finally, William Blair restated an "outperform" rating on shares of Amgen in a research note on Tuesday, June 24th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Amgen presently has an average rating of "Hold" and a consensus price target of $307.82.

Amgen Price Performance

Shares of AMGN stock traded up $4.05 on Tuesday, reaching $297.00. The company's stock had a trading volume of 1,534,132 shares, compared to its average volume of 2,841,077. The stock's fifty day simple moving average is $282.66 and its 200-day simple moving average is $287.38. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 8.70. The company has a market capitalization of $159.70 billion, a price-to-earnings ratio of 27.10, a price-to-earnings-growth ratio of 2.70 and a beta of 0.49.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.18 by $0.72. The company had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. Amgen had a return on equity of 176.11% and a net margin of 17.39%. Amgen's revenue was up 9.4% on a year-over-year basis. During the same period last year, the company earned $3.96 earnings per share. Analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.